Date: June 16, 2026 Source: The Endocrine Society Summary: A large real-world study suggests semaglutide (Ozempic, Wegovy, Rybelsus) may offer an unexpected bonus for people with type 2 diabetes: stronger protection against bone fractures while delivering greater weight loss
Pancreatitis (more common for those who have had bariatric surgery) On side effects: The most common side effects seen in patients are GI (gastrointestinal) symptoms, including nausea, vomiting, constipation and/or diarrhea

Statistical analysis For each study population, the semaglutide cohort and the comparision cohort were propensity-score matched (1:1 using nearest neighbor greedy matching with a caliper of 0.25 times the standard deviation) on covariates that are potential risk factors for AUD 57,58,59,60 including demographics, adverse socioeconomic determinants of health (e.g., problems related to education and literacy, employment and unemployment, housing and economic circumstances, social environment, upbringing, primary support group including family circumstances and various psychosocial circumstances), problems with lifestyle (e.g., tobacco use, lack of physical exercise, inappropriate diet and eating habits, high-risk sexual behavior, gambling and betting, and other problems related to lifestyle including antisocial behaviors and sleep deprivation), pre-existing medical conditions, medications, medical procedures and medical visit types (outpatient, inpatient, emergency, and virtual)

The signal of OH could be detected in the ZFO + H 2 O 2 , ZFP + H 2 O 2 , and ZFPG + Glu group, which indicated the enzyme cascade catalytic property of ZFPG NPs (Fig